European Commission approves cabozantinib for first-line kidney cancer
The European Commission has approved cabozantinib (Cabometyx) for the first-line [...]
Results from a major study might lead to reduced animal testing by pharmaceutical companies
A major, groundbreaking study carried out by Elsevier, a global [...]
Cabozantinib significantly improves overall survival in people with previously treated advanced kidney cancer
Cabozantinib significantly improves overall survival in previously treated patients with [...]
NHS to cut clinical trial bureaucracy to improve access to cutting-edge therapies
The NHS has introduced new processes to fast track research [...]
FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer
The glutaminase inhibitor, CB-839 has been granted Fast Track designation [...]
FDA grants fast track designation to glutaminase inhibitor CB-839 in combination with cabozantinib for metastatic kidney cancer
Calithera Biosciences announced earlier this week that the US Food [...]
How premature hype about drugs in clinical trials fails patients
This is an interesting blog from a cancer doctor who [...]
Alternative 2 weeks on/1 week off dosing schedule for sunitinib
The results from a phase 2 study looking at the [...]
FDA approves nivolumab-ipilimumab combination for advanced kidney cancer
The US Food and Drug Administration (FDA) has granted approval [...]
Anticancer immunotherapy that overcomes tumour resistance to immune checkpoint inhibitors
Despite some remarkable patient outcomes in recent years, most tumours [...]
